Research, Innovation & Engagement Support

Trial background

CLASP is a prospective, randomised open-label blinded-endpoint (PROBE) phase 3 multicentre trial with a primary objective to determine whether 5 days of treatment with clarithromycin in addition to usual non-macrolide antibiotic treatment for post-stroke pneumonia (PSP) improves functional outcome at 90 days.

This trial also seeks to determine whether 5 days of treatment with clarithromycin in addition to usual non-macrolide antibiotic treatment for Post Stroke Pneumonia:

• Reduces mortality at 90 days
• Increases home time by 90 days
• Reduces cardiovascular mortality at 90 days
• Reduces urgent or unplanned readmissions at 90 days
• Reduces recurrent stroke at 90 days
• Reduces major cardiovascular events at 90 days
• Improves quality of life at 90 days
• Improves stroke-related health status at 90 days
• Reduces caregiver burden at 90 days
• Is safe
• Is cost-effective from the perspective of NHS England

The trial is funded by the NIHR HTA programme with a target of 45 sites to be opened by April 2027 and 1166 participants recruited by November 2028. We aim to have the study concluded and final sites closed down by August 2029.

The trial is sponsored by the University of Glasgow and NHS Glasgow Greater Glasgow & Clyde with the Chief Investigator based at the University of Manchester.

55 sites across the UK have expressed their interest in participating in the CLASP trial - following submissions of site capability assessment forms